Render Target: STATIC
Render Timestamp: 2024-10-31T10:10:05.029Z
Commit: 23cb9f61fe67e1e9093fd644a533c4ff516a6463
XML generation date: 2024-09-26 17:16:13.120
Product last modified at: 2024-09-27T07:01:00.774Z
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72

DL-α-Difluoromethylornithine Hydrochloride (DFMO) #69294

    Product Information

    Product Usage Information

    DL-α-Difluoromethylornithine Hydrochloride (DFMO) is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 1 mg of powder in 0.42 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

    Storage

    Store lyophilized at room temperature, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 236.7 g/mol
    Purity >98%
    Molecular Formula C6H12F2N2 O2 • HCl • H2O
    CAS 96020-91-6
    Solubility Soluble in water at 25 mg/mL.

    Background

    The polyamine analog DL-α-Difluoromethylornithine Hydrochloride (DFMO) inhibits the enzyme ornithine decarboxylase (ODC), which catalyzes the rate-limiting step of polyamine biosynthesis. Originally developed to treat excessive hair growth and trypanosomiasis, DFMO was later studied as a potential therapeutic to block the development of cancers that relied on polyamine biosynthesis (1). Blocking polyamine biosynthesis with DFMO in conjunction with the drug-induced inhibition of polyamine uptake prevented or delayed tumor development in neuroblastoma-prone mice, and extended survival in rodent models of established tumors (2). Treatment with DFMO suppressed oncogene MYC expression and MYC-mediated tumorigenesis, and improved treatment of chemoresistant pancreatic ductal adenocarcinoma (3). Inhibition of ODC by DFMO blocked tumor growth in intact immunocompetent mice, but not in immunodeficient individuals. Specifically, DFMO promoted an immunological response to cancer as treatment of mice increased anti-tumor CD8+ T cell infiltration and IFN-γ production, augmented the efficacy of adoptive T cell therapy, and impaired myeloid-derived suppressor cell activity (4).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.